Lipid Metabolism — MCQs

Lipid Metabolism Indian Medical PG Practice Questions and MCQs

Question 81: According to the ATP III Classification, what is the desired level of total cholesterol?

A. < 250 mg/dL
B. < 200 mg/dL
C. < 100 mg/dL
D. < 40 mg/dL (Correct Answer)

Explanation: The **ATP III (Adult Treatment Panel III)** guidelines, established by the National Cholesterol Education Program (NCEP), provide standardized clinical classifications for serum lipid levels to assess cardiovascular risk. ### **Explanation of the Correct Answer** There appears to be a **discrepancy in the provided key**. According to standard ATP III guidelines: * **Total Cholesterol:** Desirable level is **< 200 mg/dL**. * **HDL Cholesterol:** Low (risk factor) is **< 40 mg/dL**. If the intended correct answer is **< 40 mg/dL**, the question likely refers to the threshold for **low HDL (High-Density Lipoprotein)**, not Total Cholesterol. In the context of Total Cholesterol, **Option B (< 200 mg/dL)** is the medically accurate "desirable" level. ### **Analysis of Options** * **Option A (< 250 mg/dL):** Incorrect. This exceeds the "Borderline High" threshold (200–239 mg/dL). Levels ≥ 240 mg/dL are classified as "High." * **Option B (< 200 mg/dL):** This is the **actual desired level for Total Cholesterol**. * **Option C (< 100 mg/dL):** This is the "Optimal" level for **LDL (Low-Density Lipoprotein)**, not Total Cholesterol. * **Option D (< 40 mg/dL):** This is the threshold for **Low HDL**. In clinical exams, if this is marked correct for Total Cholesterol, it is a typographical error in the question source. ### **High-Yield Clinical Pearls for NEET-PG** * **Total Cholesterol:** Desirable < 200 | Borderline 200–239 | High ≥ 240 mg/dL. * **LDL (The "Bad" Cholesterol):** Optimal < 100 | Very High ≥ 190 mg/dL. * **HDL (The "Good" Cholesterol):** Low < 40 | High (Protective) ≥ 60 mg/dL. * **Triglycerides:** Normal < 150 | Very High ≥ 500 mg/dL (Risk of pancreatitis). * **Friedewald Formula:** $LDL = Total\ Cholesterol - HDL - (Triglycerides/5)$. (Note: Invalid if TG > 400 mg/dL).

Question 82: Triacylglycerol synthesis is enhanced by which of the following hormones?

A. Co-isoleucine
B. Glucagon
C. Insulin (Correct Answer)
D. Epinephrine

Explanation: **Explanation:** **1. Why Insulin is Correct:** Insulin is the primary anabolic hormone of the body, promoting energy storage. In the "well-fed state," insulin enhances **Triacylglycerol (TAG) synthesis** (Lipogenesis) through several mechanisms: * **Glucose Uptake:** It increases glucose entry into adipocytes via GLUT-4, providing **Glycerol-3-phosphate** (the backbone for TAG). * **Enzyme Activation:** It activates **Acetyl-CoA Carboxylase**, the rate-limiting enzyme for fatty acid synthesis. * **Lipoprotein Lipase (LPL) Induction:** Insulin stimulates LPL in the capillary walls of adipose tissue, allowing the uptake of free fatty acids from chylomicrons and VLDL for storage. * **Inhibition of Lipolysis:** It inhibits Hormone-Sensitive Lipase (HSL), preventing the breakdown of stored fats. **2. Why Other Options are Incorrect:** * **Glucagon & Epinephrine:** These are catabolic hormones. They stimulate **Lipolysis** (breakdown of TAGs) by activating Hormone-Sensitive Lipase via the cAMP pathway to provide fuel during fasting or stress. They inhibit TAG synthesis. * **Co-isoleucine:** This is not a recognized hormone involved in lipid regulation; isoleucine is a branched-chain amino acid. **3. High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme of Lipogenesis:** Acetyl-CoA Carboxylase (requires Biotin). * **Rate-limiting enzyme of Lipolysis:** Hormone-Sensitive Lipase (HSL). * **The "Insulin-Glucagon Ratio":** A high ratio favors lipogenesis (storage), while a low ratio (fasting/diabetes) favors ketogenesis and lipolysis. * **Glycerol Kinase:** Adipose tissue lacks this enzyme; therefore, it must rely on glucose metabolism (DHAP) to produce Glycerol-3-phosphate for TAG synthesis. This makes fat storage dependent on insulin-mediated glucose uptake.

Question 83: Infant with carnitine deficiency forms hypoglycemia due to what reason?

A. Decreased glycolysis
B. Decreased gluconeogenesis
C. Increased utilization of glucose
D. Reduced fatty acid oxidation and ketogenesis (Correct Answer)

Explanation: **Explanation:** The primary defect in carnitine deficiency is the inability to transport long-chain fatty acids (LCFAs) across the inner mitochondrial membrane. Carnitine is essential for the **"Carnitine Shuttle"** (involving CPT-I and CPT-II). Without it, **β-oxidation of fatty acids** cannot occur. **Why Option D is correct:** In a fasting state, the body relies on fatty acid oxidation to provide the energy (ATP) and reducing equivalents (NADH) required for gluconeogenesis. Furthermore, β-oxidation produces **Acetyl-CoA**, which is an obligatory allosteric activator of **Pyruvate Carboxylase** (the rate-limiting enzyme of gluconeogenesis). Reduced β-oxidation leads to: 1. **Hypoglycemia:** Due to insufficient energy and lack of Acetyl-CoA to drive gluconeogenesis. 2. **Hypoketosis:** Since Acetyl-CoA is the precursor for ketone bodies, its absence prevents ketogenesis. This results in the classic presentation of **hypoketotic hypoglycemia**. **Why other options are incorrect:** * **A & C:** In carnitine deficiency, the body actually *increases* glucose utilization and glycolysis to compensate for the lack of fatty acid energy, which further exacerbates the hypoglycemia. * **B:** While gluconeogenesis is indeed decreased, it is a *consequence* of reduced fatty acid oxidation (Option D), which is the primary biochemical mechanism. **NEET-PG High-Yield Pearls:** * **Clinical Triad:** Hypoketotic hypoglycemia, hyperammonemia (due to urea cycle dysfunction from low ATP), and cardiomyopathy/skeletal muscle weakness. * **CPT-I vs. CPT-II:** CPT-I is located in the outer mitochondrial membrane and is inhibited by **Malonyl-CoA** (the first committed intermediate of fatty acid synthesis). * **Treatment:** Avoid prolonged fasting; provide a diet high in carbohydrates and medium-chain triglycerides (MCTs), as MCTs do not require the carnitine shuttle to enter the mitochondria.

Question 84: A 12-year-old intellectually disabled boy presents with short stature, protuberant abdomen with an umbilical hernia, and a prominent forehead. His vision is normal, and his parents are unaffected. What is the metabolic defect in this disorder?

A. L-Iduronidase
B. Iduronate Sulfatase (Correct Answer)
C. Aryl Sulfatase B
D. Beta-Glucuronidase

Explanation: ### **Explanation** The clinical presentation of intellectual disability, short stature, protuberant abdomen (hepatosplenomegaly), umbilical hernia, and coarse facial features (prominent forehead) is characteristic of **Mucopolysaccharidosis (MPS)**. The defining clue in this case is the **absence of corneal clouding** ("vision is normal") and the fact that the parents are unaffected (suggesting **X-linked recessive** inheritance, as it primarily affects males). #### **Why Option B is Correct** **Hunter Syndrome (MPS II)** is caused by a deficiency of **Iduronate Sulfatase**. It is unique among the mucopolysaccharidoses because it is **X-linked recessive** (all others are autosomal recessive) and **lacks corneal clouding**. The enzyme deficiency leads to the accumulation of Heparan sulfate and Dermatan sulfate. #### **Why Other Options are Incorrect** * **Option A: L-Iduronidase:** Deficiency causes **Hurler Syndrome (MPS IH)**. While it presents with similar skeletal and facial features, it is characterized by **severe corneal clouding** and follows an autosomal recessive pattern. * **Option C: Aryl Sulfatase B:** Deficiency causes **Maroteaux-Lamy Syndrome (MPS VI)**. Patients have severe skeletal deformities and corneal clouding but usually have **normal intelligence**. * **Option D: Beta-Glucuronidase:** Deficiency causes **Sly Syndrome (MPS VII)**, a very rare form with variable severity, often involving hydrops fetalis or skeletal dysplasia. #### **High-Yield Clinical Pearls for NEET-PG** * **Mnemonic for Hunter:** "The **Hunter** needs **clear eyes** to see the **X** (X-linked) on the target." (Hunter = No corneal clouding + X-linked). * **Accumulated Substances:** Both Hurler and Hunter syndromes involve the accumulation of **Dermatan sulfate and Heparan sulfate**. * **Diagnosis:** Initial screening is via urinary GAG (glycosaminoglycan) levels; definitive diagnosis is by enzyme assay or genetic testing. * **Treatment:** Enzyme Replacement Therapy (ERT) with **Idursulfase** is available for Hunter Syndrome.

Question 85: What is the first fatty acid synthesized in fatty acid synthesis?

A. Palmitic acid (Correct Answer)
B. Stearic acid
C. Oleic acid
D. Pantothenic acid

Explanation: ### Explanation **1. Why Palmitic Acid is Correct:** Fatty acid synthesis (De novo lipogenesis) occurs primarily in the cytosol of the liver and lactating mammary glands. The process is catalyzed by the multi-enzyme complex **Fatty Acid Synthase (FAS)**. This enzyme system functions as a dimer and adds two-carbon units (from Malonyl-CoA) sequentially to a growing chain. The synthesis automatically terminates once the chain reaches **16 carbons**, resulting in the production of **Palmitic acid (Palmitate)**. It is the primary end-product because the thioesterase domain of the FAS complex is specific for the 16-carbon chain length. **2. Why Other Options are Incorrect:** * **Stearic acid (18:0):** This is a longer-chain fatty acid. While it can be produced from palmitate, it requires **elongation** by enzymes located in the mitochondria and endoplasmic reticulum, occurring *after* the initial synthesis. * **Oleic acid (18:1):** This is a monounsaturated fatty acid. It is formed by the **desaturation** of stearic acid. FAS cannot produce unsaturated fatty acids directly. * **Pantothenic acid:** This is Vitamin B5. It is a precursor for **Coenzyme A (CoA)** and the **Acyl Carrier Protein (ACP)**, which are essential *cofactors* for synthesis, not the fatty acid product itself. **3. Clinical Pearls & High-Yield Facts:** * **Rate-limiting enzyme:** Acetyl-CoA Carboxylase (ACC), which requires **Biotin** (B7). * **Reducing power:** **NADPH** is the essential electron donor, primarily supplied by the Hexose Monophosphate (HMP) Shunt. * **Citrate Shuttle:** Since Acetyl-CoA cannot cross the mitochondrial membrane, it is transported to the cytosol as **Citrate**. * **Inhibitor:** Palmitoyl-CoA (the end product) provides feedback inhibition to ACC.

Question 86: Which type of lipoprotein is most important in causing coronary artery disease (CAD)?

A. HDL
B. LDL (Correct Answer)
C. VLDL
D. Triglycerides

Explanation: **Explanation:** **Low-Density Lipoprotein (LDL)** is the primary lipoprotein implicated in the pathogenesis of atherosclerosis and coronary artery disease (CAD). Often termed **"Bad Cholesterol,"** LDL is responsible for transporting cholesterol from the liver to peripheral tissues. When present in excess, LDL particles (especially small dense LDL) penetrate the arterial intima, undergo oxidation, and are engulfed by macrophages to form **foam cells**. This process initiates the formation of atherosclerotic plaques, leading to luminal narrowing and myocardial ischemia. **Analysis of Incorrect Options:** * **HDL (High-Density Lipoprotein):** Known as "Good Cholesterol," it mediates **reverse cholesterol transport**, moving cholesterol from tissues back to the liver. High levels are cardioprotective. * **VLDL (Very Low-Density Lipoprotein):** Primarily transports endogenous triglycerides. While it is a precursor to LDL, it is not the primary direct driver of CAD compared to LDL. * **Triglycerides:** While elevated triglycerides are an independent risk factor for cardiovascular disease, they are more strongly associated with pancreatitis when severely elevated. **High-Yield Clinical Pearls for NEET-PG:** * **Friedewald Formula:** LDL = Total Cholesterol – HDL – (Triglycerides/5). (Note: This is invalid if TG >400 mg/dL). * **Apolipoprotein B-100** is the primary structural protein found in LDL, VLDL, and IDL. It is a key marker for atherogenic particles. * **Target Levels:** In high-risk CAD patients, the goal is often to keep LDL <70 mg/dL. * **Oxidized LDL** is the most atherogenic form as it is not recognized by normal LDL receptors but is taken up by "Scavenger Receptors" on macrophages.

Question 87: Niemann-Pick disease is due to deficiency of which enzyme?

A. Sphingomyelinase (Correct Answer)
B. Ceramidase
C. Galactosidase
D. Glucosidase

Explanation: **Explanation:** Niemann-Pick disease (Types A and B) is a lysosomal storage disorder characterized by the deficiency of **Acid Sphingomyelinase**. This enzyme is responsible for the hydrolysis of sphingomyelin into ceramide and phosphorylcholine. Its deficiency leads to the pathological accumulation of sphingomyelin in the reticuloendothelial system (liver, spleen, and bone marrow) and the central nervous system. **Analysis of Options:** * **Sphingomyelinase (Correct):** Deficiency leads to Niemann-Pick disease. Histologically, this is marked by "Foam cells" (lipid-laden macrophages) in the bone marrow. * **Ceramidase:** Deficiency causes **Farber disease**, characterized by painful joint swelling, hoarseness (laryngeal involvement), and subcutaneous nodules. * **Galactosidase:** Deficiency of $\beta$-Galactosidase leads to **Krabbe disease** (accumulation of galactocerebroside), while deficiency of $\alpha$-Galactosidase A leads to **Fabry disease**. * **Glucosidase:** Deficiency of $\beta$-Glucosidase (Glucocerebrosidase) leads to **Gaucher disease**, the most common lysosomal storage disorder, characterized by "wrinkled tissue paper" appearance of macrophages. **High-Yield Clinical Pearls for NEET-PG:** * **Niemann-Pick Type A:** Presents in infancy with hepatosplenomegaly, rapid neurodegeneration, and a **Cherry-red spot** on the macula (also seen in Tay-Sachs, but Tay-Sachs lacks hepatosplenomegaly). * **Niemann-Pick Type C:** Due to a defect in cholesterol transport ($NPC1/NPC2$ genes), not a primary enzyme deficiency. * **Mnemonic:** "No-man picks (Niemann-Pick) his nose with a **Foamy** finger" (Foam cells).

Question 88: What is the effect of estrogen in pre-menopausal women on the lipid profile?

A. Decreased high-density lipoproteins
B. Increased low-density lipoproteins
C. Increased high-density lipoproteins (Correct Answer)
D. Increased total cholesterol

Explanation: **Explanation:** Estrogen plays a pivotal role in lipid metabolism, which explains why pre-menopausal women generally have a lower risk of cardiovascular disease compared to men and post-menopausal women. **Why the correct answer is right:** Estrogen exerts a cardioprotective effect primarily by **increasing High-Density Lipoprotein (HDL)** levels. It achieves this by stimulating the synthesis of Apolipoprotein A-I (the primary protein in HDL) and inhibiting the activity of **Hepatic Lipase**, the enzyme responsible for HDL degradation. Additionally, estrogen enhances the expression of LDL receptors in the liver, leading to **decreased Low-Density Lipoprotein (LDL)** levels. **Analysis of Incorrect Options:** * **A. Decreased HDL:** Incorrect. Estrogen increases HDL by reducing its clearance. * **B. Increased LDL:** Incorrect. Estrogen actually lowers LDL levels by increasing the clearance of LDL particles from the circulation via up-regulation of hepatic LDL receptors. * **D. Increased total cholesterol:** Incorrect. While estrogen can slightly increase VLDL (triglycerides), the overall effect is a reduction in total cholesterol due to the significant drop in LDL. **NEET-PG High-Yield Pearls:** * **Post-menopausal shift:** After menopause, the drop in estrogen leads to an increase in LDL and a decrease in HDL, significantly increasing the risk of Atherosclerotic Cardiovascular Disease (ASCVD). * **Triglyceride Paradox:** Oral estrogen therapy can actually **increase serum triglycerides** by stimulating VLDL synthesis in the liver. * **Enzyme Inhibition:** Remember that estrogen inhibits **Hepatic Lipase**; this is a common "fact-check" point in biochemistry exams.

Question 89: Which of the following statements regarding acetyl CoA carboxylase is false?

A. It is the rate-limiting enzyme of fatty acid synthesis.
B. It is a component of the fatty acid synthase complex. (Correct Answer)
C. It is activated by citrate.
D. It requires biotin.

Explanation: **Explanation:** The correct answer is **B** because **Acetyl CoA Carboxylase (ACC)** and the **Fatty Acid Synthase (FAS) complex** are two distinct, separate entities in the cytoplasm. While both are essential for de novo lipogenesis, ACC performs the preliminary "commitment step," whereas the FAS complex is a multi-enzyme system that elongates the fatty acid chain. **Analysis of Options:** * **Option B (False/Correct):** ACC is not part of the FAS complex. ACC converts Acetyl CoA to Malonyl CoA. Only after Malonyl CoA is formed does the FAS complex take over to catalyze the remaining reactions. * **Option A (True):** ACC is the **rate-limiting and committed step** of fatty acid synthesis. Its activity determines the flux of carbons into the lipogenic pathway. * **Option C (True):** ACC is regulated by **allosteric activation**. Citrate (signaling high energy) promotes the polymerization of inactive ACC dimers into active long filaments. Conversely, Palmitoyl CoA (end-product) inhibits it. * **Option D (True):** ACC is a **biotin-dependent enzyme**. Like most carboxylases (e.g., Pyruvate carboxylase), it requires Biotin (Vitamin B7), ATP, and $\text{CO}_2$ (as bicarbonate) to function. **High-Yield Clinical Pearls for NEET-PG:** * **Hormonal Control:** ACC is activated by **Insulin** (via dephosphorylation) and inhibited by **Glucagon/Epinephrine** (via phosphorylation by AMPK). * **The "ABC" Rule:** Most carboxylases require **A**TP, **B**iotin, and **C**$\text{O}_2$. * **Malonyl CoA Inhibition:** Malonyl CoA (produced by ACC) inhibits **Carnitine Palmitoyltransferase-I (CPT-I)**, preventing the newly synthesized fatty acids from entering the mitochondria for oxidation (preventing a futile cycle).

Question 90: All the following are associated with increased risk of coronary heart disease except?

A. Familial hypercholesterolemia
B. Familial hyperacylglycerolemia
C. Familial hyperalphalipoproteinemia (Correct Answer)
D. Hepatic lipase deficiency

Explanation: **Explanation:** The core concept tested here is the distinction between pro-atherogenic and anti-atherogenic lipoproteins. **Why Option C is Correct:** **Familial Hyperalphalipoproteinemia** is a rare genetic condition characterized by abnormally high levels of **High-Density Lipoprotein (HDL)**, often due to a deficiency in Cholesteryl Ester Transfer Protein (CETP). Since HDL is responsible for "Reverse Cholesterol Transport"—shuttling cholesterol from peripheral tissues back to the liver—it is highly cardioprotective. Therefore, this condition is associated with a **decreased** risk of coronary heart disease (CHD) and increased longevity. **Why the other options are incorrect:** * **A. Familial Hypercholesterolemia:** Caused by a defect in LDL receptors, leading to extremely high levels of LDL ("bad cholesterol"). This is a major risk factor for premature atherosclerosis and myocardial infarction. * **B. Familial Hyperacylglycerolemia (Hypertriglyceridemia):** Elevated VLDL and triglycerides are independent risk factors for CHD and are often associated with metabolic syndrome and low HDL. * **C. Hepatic Lipase Deficiency:** This enzyme is crucial for converting IDL to LDL and converting HDL2 to HDL3. Its deficiency leads to the accumulation of cholesterol-rich VLDL remnants and IDL (Beta-VLDL), which are highly atherogenic. **High-Yield Clinical Pearls for NEET-PG:** * **HDL (The "Good" Lipoprotein):** Contains **Apo A-I**. It is anti-atherogenic, anti-inflammatory, and anti-oxidant. * **LDL (The "Bad" Lipoprotein):** Contains **Apo B-100**. It is the primary carrier of cholesterol to peripheral tissues. * **CETP Inhibitors:** Drugs like Anacetrapib aim to mimic familial hyperalphalipoproteinemia to raise HDL levels, though their clinical utility in reducing CV events remains a subject of research. * **Friedewald Formula:** LDL = Total Cholesterol – (HDL + TG/5). (Note: Not applicable if TG >400 mg/dL).

Practice by Chapter

Lipid Classification and Chemistry

Practice Questions

Fatty Acid Oxidation

Practice Questions

Ketone Body Metabolism

Practice Questions

Fatty Acid Synthesis

Practice Questions

Metabolism of Triacylglycerols

Practice Questions

Phospholipid Metabolism

Practice Questions

Cholesterol Metabolism and Biosynthesis

Practice Questions

Bile Acids and Bile Salts

Practice Questions

Lipoprotein Metabolism and Transport

Practice Questions

Dyslipidemias and Atherosclerosis

Practice Questions

Prostaglandins and Eicosanoids

Practice Questions

Fatty Liver and Lipotropic Factors

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free